EP0242233A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Lymphokines for use in the treatment of infections
Assignee: Cetus Oncology Corp
•
Filing: 1987-04-16
•
Granted: —
•
Expires: 2007-04-16
Abstract
Abstract Infections in mammalian hosts may be treated therapeutically or prophylactically with an effective amount of at least one lymphokine before or after host infection, the amount being sufficient to achieve at least 50% protection of the host. Preferably, the lymphokine is IL-2 or a combination of TNF and IL-2 or INF and IFN-y. Also preferably the infection is bacterial and is being treated prophylactically. The combination of TNF and IL-2 or TNF and IFN-γ is administered in synergistically effective amounts.
Inventors
- 👤 Kong-Teck Chong
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-09 10:25
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/19; A61K38/20; A61K38/2013; A61K38/191; A61K38/21; A61K38/217; A61P; A61P31/00; A61P37/00; A61P37/02; A61P37/04
Claims Analysis
Total Claims: 17
Claim 1
Independent Claim
63 words
The use of a mammalian lymphokine in preparing a medicament for the prophylactic or therapeutic treatment of infections in mammalian hosts by administering an effective amount of at least one lymphokine from a mammalian species to the host before or after infection of the host, wherein the amount of lymphokine is a sufficient dose to achieve at least 50% protection of the host.
Claim 2
Dependent Claim
63 words
The use of a mammalian lymphokine in preparing a medicament for the prophylactic or therapeutic treatment of infections in mammalian hosts by administering an effective amount of at least one lymphokine from a mammalian species to the host before or after infection of the host, wherein the amount of lymphokine is a sufficient dose to achieve at least 50% protection of the host.
Claim 3
Dependent Claim
19 words
A method according to claim 1 wherein the lymphokine is from a human source and the host is human.
Claim 4
Dependent Claim
18 words
A method according to claim 1 or 2 wherein the lymphokine is IL-2 and the treatment is prophylactic.
Claim 5
Independent Claim
36 words
A method according to any one of claims 1 to 3 wherein the amount of lymphokine is a sufficient dose to achieve at least 70% protection of the host and the infection is a bacterial infection.
Claim 6
Dependent Claim
65 words
S. The use of at least two mammalian lymphokines in providing medication for the prophylactic or therapeutic treatment of infections in mammalian hosts by administering an effective amount of at least two lymphokines from a mammalian species to the host before or after infection of the host, wherein the amount of lymphokine is a sufficient does to achieve at least 50% protection of the host.
Claim 7
Dependent Claim
65 words
S. The use of at least two mammalian lymphokines in providing medication for the prophylactic or therapeutic treatment of infections in mammalian hosts by administering an effective amount of at least two lymphokines from a mammalian species to the host before or after infection of the host, wherein the amount of lymphokine is a sufficient does to achieve at least 50% protection of the host.
Claim 8
Dependent Claim
21 words
A method according to claim 5 wherein the lymphokines are interleukin-2 and tumor necrosis factor or tumor necrosis factor and interferon.
Claim 9
Dependent Claim
42 words
The use of IL-2 in medicament production for a method for prophylactic or therapeutic treatment of infections in mammalian hosts by administering at least 100,000 units of IL-2 from a mammalian species to the host before or after infection of the host.
Claim 10
Dependent Claim
42 words
The use of IL-2 in medicament production for a method for prophylactic or therapeutic treatment of infections in mammalian hosts by administering at least 100,000 units of IL-2 from a mammalian species to the host before or after infection of the host.
Claim 11
Dependent Claim
40 words
A lymphokine or lymphokines form a mammalian speciesfor use in the prophylactic therapeutic treatment of infection in a mammalian host by the administration of the said lymphokine(s) in an amount sufficient to achieve at least 50% protection of the host.
Claim 12
Dependent Claim
40 words
A lymphokine or lymphokines form a mammalian speciesfor use in the prophylactic therapeutic treatment of infection in a mammalian host by the administration of the said lymphokine(s) in an amount sufficient to achieve at least 50% protection of the host.
Claim 13
Dependent Claim
45 words
A composition suitable for parenteral administration to mammalian hosts for prophylactic or therapeutic treatment of infections comprising a mixture of tumor necrosis factor (TNF) and either interleukin-2 (IL-2) or interferon-gamma (IFN-y) in synergistically effective amounts, wherein the TNF, IL-2, and IFN-yare from a mammalian species.
Claim 14
Dependent Claim
45 words
A composition suitable for parenteral administration to mammalian hosts for prophylactic or therapeutic treatment of infections comprising a mixture of tumor necrosis factor (TNF) and either interleukin-2 (IL-2) or interferon-gamma (IFN-y) in synergistically effective amounts, wherein the TNF, IL-2, and IFN-yare from a mammalian species.
Claim 15
Dependent Claim
39 words
A composition according to claim 9 wherein the TNF and IL-2 or IFN-y are from human sources and are recombinant proteins and wherein the composition further comprises a pharmaceutically acceptable carrier medium for the TNF and IL-2 or IFN-γ.
Claim 16
Independent Claim
54 words
A method of making a therapeutic or prophylactic formulation for parenteral administration to mammalian hosts for prophylactic or therapeutic treatment of infections comprising formulating together a mixture of tumor necrosis factor (TNF) and either interleukin-2 (IL-2) or interferon-gamma (IFN-y) in synergistically effective amounts, wherein the TNF, IL-2, and IFN-Y are from a mammalian species.
Claim 17
Independent Claim
54 words
A method of making a therapeutic or prophylactic formulation for parenteral administration to mammalian hosts for prophylactic or therapeutic treatment of infections comprising formulating together a mixture of tumor necrosis factor (TNF) and either interleukin-2 (IL-2) or interferon-gamma (IFN-y) in synergistically effective amounts, wherein the TNF, IL-2, and IFN-Y are from a mammalian species.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.